You are here
MedEffect Canada - Advisories and Recalls for Health Professionals
Stay informed on new safety information for health professionals related to marketed health products. This information helps health professionals and their patients to make informed decisions about the use of therapeutic products.
Updated: 12 min 34 sec ago
Metal-on-Metal Hip Implants - Information for Orthopaedic Surgeons Regarding Patient Management Following Surgery
Health Canada has issued a Health Care Professional letter to Canadian orthopaedic surgeons informing them about potential health risks and recommending patient management strategies following metal-on-metal (MoM) hip implant surgery.
Categories: Adverse Reactions
Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk
Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).
Categories: Adverse Reactions
Summary Basis of Decision Phase II: Posting of the Summary Report of External Consultations [2012-05-07]
The report provides a summary of consultations with external stakeholders regarding changes proposed for Phase II of the Summary Basis of Decision (SBD) Project.
Categories: Adverse Reactions
Benlysta (belimumab) - Association with Hypersensitivity and Infusion Reactions
Cases of severe, sometimes fatal, delayed hypersensitivity reactions, associated with Benlysta (belimumab) treatment have been reported in patients with systemic lupus erythematosus.
Categories: Adverse Reactions
Revlimid (lenalidomide) - Association with an Increased Risk of Second Cancers
Health Canada has reviewed new safety information on the anti-cancer drug REVLIMID. The label has been updated to reflect the possible increased risk of second cancers in patients receiving REVLIMID for the treatment of multiple myeloma.
Categories: Adverse Reactions